Macgest SR 200 Tablet contains 200 mg of natural micronized progesterone, a bioidentical hormone essential for regulating the menstrual cycle and maintaining pregnancy. This sustained-release formulation ensures a gradual and consistent release of progesterone, optimizing therapeutic efficacy and minimizing fluctuations in hormone levels. Macgest SR 200 is primarily indicated for the treatment of progesterone deficiency states, including luteal phase support in assisted reproductive technology (ART), prevention of threatened or recurrent miscarriage, and management of menstrual disorders such as amenorrhea and abnormal uterine bleeding. Additionally, it is used in hormone replacement therapy (HRT) for postmenopausal women to counteract the effects of estrogen on the endometrium, thereby reducing the risk of endometrial hyperplasia. The natural micronized form enhances absorption and bioavailability compared to synthetic analogs. Macgest SR 200 should be administered under medical supervision, with dosage tailored according to the clinical condition and patient response. Contraindications include known hypersensitivity to progesterone, unexplained vaginal bleeding, active thromboembolic disorders, and hormone-dependent malignancies. Common adverse effects may include dizziness, headache, breast tenderness, and mood changes. Patient monitoring is advised to ensure therapeutic outcomes and detect any adverse reactions promptly.